Background
==========

The incidence of diabetic cardiovascular autonomic neuropathy (DCAN) as a diabetic microvascular complication \[[@b1-medscimonit-23-5354],[@b2-medscimonit-23-5354]\] is rising rapidly throughout the world \[[@b3-medscimonit-23-5354]\]. The prevalence of DCAN in diabetic patients is estimated at 30--60% \[[@b4-medscimonit-23-5354]\]. The damage due to DCAN involves autonomic nerve fibers that innervate the heart and blood vessels and consequentially contributes to abnormalities in heart rate control and vascular dynamics \[[@b5-medscimonit-23-5354]--[@b8-medscimonit-23-5354]\]. This disease carries an increased risk of cardiovascular morbidity and mortality in diabetic patients \[[@b9-medscimonit-23-5354],[@b10-medscimonit-23-5354]\]. Short-term heart rate variability (HRV) testing is sensitive and non-invasive, and it can easily be applied as a test of cardiovascular autonomic function test on a large scale \[[@b4-medscimonit-23-5354],[@b6-medscimonit-23-5354],[@b11-medscimonit-23-5354]\]. Our previous study provided evidence that a short-term HRV test had high sensitivity (Sen) and specificity (Spe) for DCAN diagnosis and that the HRV test was not inferior to the traditional Ewing's test for DCAN \[[@b12-medscimonit-23-5354],[@b13-medscimonit-23-5354]\].

Early detection of patients with DCAN is important toward decreasing cardiovascular morbidity and mortality. An accurate and simple screening tool that identifies those at high risk for DCAN would be of great value in clinical and public health practice. During the past decade, several risk score systems have been developed for diabetes, primarily in white populations \[[@b14-medscimonit-23-5354]--[@b19-medscimonit-23-5354]\]. However, few diabetes risk scores have been based on Asian populations \[[@b20-medscimonit-23-5354]--[@b22-medscimonit-23-5354]\]. In our previous studies, we developed a screening system to predict people with a high risk of cardiovascular autonomic dysfunction neuropathy (CAN) in the Chinese population but not in diabetic patients \[[@b23-medscimonit-23-5354],[@b24-medscimonit-23-5354]\].

Recently, we conducted a risk association analysis of metabolic indices involved in blood pressure profiles, lipid profiles, and blood glucose profiles for DCAN, and our results suggest that these profiles are significantly and independently associated with DCAN \[[@b25-medscimonit-23-5354]--[@b27-medscimonit-23-5354]\]. Moreover, the combination of these risk factors has predictive value for DCAN. However, to the best of our knowledge, there are no risk score systems for DCAN screening in diabetic patients worldwide. Based on our previous studies \[[@b25-medscimonit-23-5354]--[@b28-medscimonit-23-5354]\], we hypothesized that risk factors related to DCAN can be used to create a simple risk score system for DCAN screening.

Material and Methods
====================

The aim, design, and setting of the study
-----------------------------------------

In this study, our aim was to create a screening system for identifying and predicting DCAN in Chinese diabetic patients. Like our previous studies \[[@b25-medscimonit-23-5354]--[@b29-medscimonit-23-5354]\], this study was based on data from a community-based cohort in China.

The characteristics of participants
-----------------------------------

Association analysis was conducted using diabetic patient data from the cross-sectional study sample toward development of a screening system for DCAN. Of these subjects, 455 diabetic participants with complete clinical baseline data were available for risk analysis of DCAN. To create an external dataset, 115 diabetic patients with the same inclusion and exclusion criteria were recruited as an independent, external cohort from healthy examination centers and other sources. All participants freely signed informed consent forms before the study. The Ethics Committee of Huashan Hospital approved this work. The methods were carried out in accordance with the approved guidelines.

Measurement
-----------

Demographic information and assessments of glucose profiles, lipid profiles, renal profiles, and medical history were detailed in earlier studies \[[@b25-medscimonit-23-5354]--[@b29-medscimonit-23-5354]\]. The definitions of hypertension (HTN), body mass index (BMI), diabetes mellitus (DM), and metabolic syndrome (MetS) were also detailed in earlier studies \[[@b25-medscimonit-23-5354]--[@b29-medscimonit-23-5354]\]. As we discussed in an earlier study \[[@b25-medscimonit-23-5354],[@b26-medscimonit-23-5354],[@b29-medscimonit-23-5354]\], short-term HRV tests can be used for the evaluation of cardiovascular autonomic function, and we used short-term HRV tests in this study. The protocol for the short-term HRV test was detailed earlier \[[@b25-medscimonit-23-5354]--[@b27-medscimonit-23-5354]\]. The definition of DCAN was based on at least 2 abnormal results from cardiovascular autonomic function testing \[[@b4-medscimonit-23-5354],[@b25-medscimonit-23-5354]--[@b28-medscimonit-23-5354]\].

Development and validation of the screening system
--------------------------------------------------

The methodology used for the development and validation of our screening system was similar to that used in our previous work \[[@b28-medscimonit-23-5354]\]. Firstly, the association analysis for DCAN was performed. Significant association factors for DCAN were estimated using univariate logistic regression (ULR) analysis. Secondly, the parameters of the screening system were validated. The β-coefficients for the associated factors of DCAN were estimated using multiple variable logistic regression analysis (MLR). The MLR model was developed using the stepwise backward elimination method and included significant simple variables (alpha level=5%). Thirdly, the screening system was created. A simple scoring system was developed based on a sum score that was derived for each participant by adding the score of each variable in the MLR model. Finally, the performance validation for the screening system was conducted. Similar to our earlier study \[[@b28-medscimonit-23-5354]\], the area under the curve (AUC) of the receiver operating characteristic (ROC) curve was used to estimate the performance of the screening system for DCAN. The Youden Index, which is the maximum sum of the Sen and Spe, was computed. In addition, the cutoff scores for low and high risk of DCAN were evaluated to calculate the optimal positive predictive value (PPV) and the negative predictive value (NPV). The parameters involved in the ROC curve analysis included Sen, Spe, Youden Index, PPV, and NPV. The proportion of individuals who needed subsequent testing was also evaluated as a parameter (%Need). These parameters were evaluated for the validation set, total sample, and external set. The bootstrapping technique was employed to compute confidence intervals (CIs) for these parameters \[[@b30-medscimonit-23-5354]\].

Results
=======

Characteristics of subjects
---------------------------

As was detailed earlier, and as shown in [Table 1](#t1-medscimonit-23-5354){ref-type="table"} \[[@b25-medscimonit-23-5354],[@b26-medscimonit-23-5354]\], the characteristics of the 455 diabetic patients were reported. The average age of the total sample and the external set was 62.8 years and 58.34 years, respectively. The mean heart rate (HR) was 75 bpm for the total sample. The prevalence of DCAN was 29.01% and 39.39% in the total sample and external set, respectively. The total sample was randomly divided into the exploratory set (n=237) and the validation set (n=218). There were no significant differences in the baseline characteristics between these 2 sets (P\<0.05 for all).

Development and validation of the screening model
-------------------------------------------------

As was discussed in earlier studies \[[@b25-medscimonit-23-5354]--[@b27-medscimonit-23-5354]\], ULR analysis showed associated factors for DCAN, including age, BMI, FPG, PBG, FINS, TG, resting HR, DM duration, HTN duration, and MetS (P\<0.05 for all). The simple association factors of age, BMI, DM duration, and HR were included in the final MLR model (P\<0.05 for all; [Table 2](#t2-medscimonit-23-5354){ref-type="table"}). The DCAN prevalence was 20.83%, 24.71%, and 36.36% for the total sample, validation set, and external set, respectively, according to age ([Figure 1](#f1-medscimonit-23-5354){ref-type="fig"}). There were no significant differences among the 3 groups (P\<0.001 for difference and P\<0.001 for a trend). There was a significant difference found in the DCAN prevalence between the 2 groups according to BMI (27.79% *vs.* 44.12%, P=0.004). The DCAN prevalence was 7.01%, 18.75%, 36.67%, and 64.29% in the 4 groups, respectively, according to resting HR (P\<0.001 for difference and P\<0.001 for a trend). There were significant differences in DCAN prevalence among the 4 groups according to DM duration (18.18%, 26.35%, 36.25%, 51.72%, respectively, with P\<0.001 for difference and P\<0.001 for a trend).

The maximum score possible in our screening model was 25. The optimal cutoff value was determined to be 12 and parameters were evaluated at this cutoff point (Sen=80.77%, Spe=68.21%, Youden Index=48.98%, and %Need=34.33%, [Table 3](#t3-medscimonit-23-5354){ref-type="table"}; and AUC=0.779, [Figure 2](#f2-medscimonit-23-5354){ref-type="fig"}). There were no significant differences in the characteristics of the validation cohort and exploratory set ([Table 1](#t1-medscimonit-23-5354){ref-type="table"}). The AUC for the total sample, validation set, and external set was 0.798 (95% CI 0.752--0.844; [Figure 2](#f2-medscimonit-23-5354){ref-type="fig"}), 0.756 (95% CI 0.705--0.808), and 0.729 (95% CI 0.601--0.857), respectively. The Spe, PPV, NPV, and%Need were similar among the 3 sets, whereas the Sen tended to be higher in the exploratory set than the validation set.

Performance analysis for the screening model
--------------------------------------------

For clinical practice, 2 cutoff points were selected to divide the total sample into 3 groups: a low risk group (score 0--7), a medium risk group (score 8--17), and a high-risk group (score 18--25) ([Table 4](#t4-medscimonit-23-5354){ref-type="table"}). In the total sample, at the cutoff point of 7, the Sen and NPV were 97.22% and 95.69%, respectively. The percentage of individuals in the low risk group was 18.65% in the total sample. Additionally, in the total sample, at the cutoff point of 18, the Spe and PPV were 98.88% and 90.05%, respectively. The percentage of individuals in the high-risk group was 8.81% in the total sample.

In the external dataset, the Sen at the cutoff point of 7 and the Spe at the cutoff point of 18 were 96.15% and 97.50%, respectively. In addition, the NPV was 92.63% at the cutoff point of 7, and the PPV was 85.71% at the cutoff point of 18. The 2 cutoff points have a high prediction rate for the risk of DCAN. This was the highest proportion of individuals with a score of 12--13 (18.36% in the total sample; [Figure 3](#f3-medscimonit-23-5354){ref-type="fig"}). The DCAN prevalence increased as the DCAN score increased in the total sample. The highest DCAN prevalence was more than 75.00% in subjects with a score of 19--25 (data not shown).

Comparison of DCAN subjects with low and high scores
----------------------------------------------------

There were significantly higher values for resting HR and DM duration in DCAN subjects with high scores as compared with those with low scores (P\<0.001, [Table 5](#t5-medscimonit-23-5354){ref-type="table"}), while there were lower HDL levels in DCAN subjects with high scores (P=0.001). No significant differences were found in the other variables between the 2 groups (P\>0.05 for all).

Discussion
==========

In this community-based study, short-term HRV was measured non-invasively using a power spectral analysis to evaluate the cardiovascular autonomic (CA) function because this test has good reproducibility and is practical for use in clinical practice. More importantly, this study resulted, to the best of our knowledge, in the first risk score system for DCAN screening, which can be applied not only in a Chinese population but also globally. We employed MLR methods to develop the DCAN risk score system in the exploratory set and confirmed them in another validation set and in the total sample. Finally, a DCAN screening system was created for identifying DCAN in Chinese diabetic patients.

For convenience and low cost, our screening system includes age, BMI, DM duration, and resting HR, allowing people to evaluate their risk of DCAN through simple calculations. The highest DCAN prevalence was more than 75.00% in subjects with a score of 19--25. It has been recommended that ROC curves be employed to evaluate the performance of screening models and diagnostic tests, which we used \[[@b28-medscimonit-23-5354]\]. At a cutoff score of 12, the screening system had a high Sen of 80.77% in the exploratory set and a low%Need of 34.33%. Importantly, the scoring system, which is derived from a simple model without blood tests, performed well when it was validated in an independent cohort. The results confirmed that our risk score system performs well in the prediction of DCAN. The optimal cutoff score determined for the external validation set was identical to the optimal cutoff score determined for the total sample, further confirming the utility of the cutoff score.

Several prior studies explored DM risk scores in various populations, and most of them were developed with Caucasian populations \[[@b14-medscimonit-23-5354]--[@b19-medscimonit-23-5354]\], while only a few risk scores were based on Asian populations, including Chinese populations \[[@b20-medscimonit-23-5354]--[@b22-medscimonit-23-5354],[@b31-medscimonit-23-5354]\]. However, no DCAN risk score systems have been developed for diabetic populations prior to this study. Previously, we reported that, in the absence of a gold standard, a short-term HRV test for DCAN diagnosis could be used with high Sen and Spe. In our previous study, Bayesian analysis was applied for estimating diagnostic parameters for DCAN in Chinese diabetic patients \[[@b13-medscimonit-23-5354]\]. Our findings are important for the clinical diagnosis of DCAN in diabetic patients. Additionally, we previously developed a risk score system to predict people at high risk of CAN in a random sample of the Chinese population \[[@b28-medscimonit-23-5354]\]. That screening system consists of simple parameters -- age, BMI, HTN, and resting HR -- that make it more convenient and less expensive than other models based on complex cardiovascular autonomic reflex tests. Our model enabled detection of 74.24% of individuals with previously diagnosed CAN who had risk scores between 16 and 37 and decreased%Need to 37.23% \[[@b24-medscimonit-23-5354]\]. In the present study, the risk system had higher predictive performance for screening DCAN in the Chinese population.

In this study, the prevalence of DCAN ranged from 28% to 36% in our samples. The estimated DCAN prevalence in DM patients was found to be 30% to 60% in other studies \[[@b4-medscimonit-23-5354],[@b32-medscimonit-23-5354]\], indicating that our results were consistent with these studies. Generally, a screening system that includes simple factors cannot have a 100% Sen \[[@b28-medscimonit-23-5354]\]. This is partly because the variables of a screening system cannot completely represent differences between false-negative and true-positive individuals. Additionally, we found that overweight or obese DCAN patients can have normal resting HR due to both an impaired sympathetic and parasympathetic nervous system. The comparison analysis of true-positive and false-negative groups indicated that there were differences in the HDL levels.

The simple model that we developed to screen DCAN in Chinese diabetic patients is based on several simple variables, which are easy to assess in clinical practice. This screening system could also be conveniently used in primary care. The possibility of selection bias in this study was reduced by using a community-based population. The screening system was found to be stable, as demonstrated by internal validation. Our study showed that the screening system could efficiently identify diabetic patients with high risks of DCAN, depending on the risk score cutoff point. The screening system could be particularly useful as an effective and practical screening tool to enhance people's awareness of DCAN. Diabetic patients with high-risk scores may benefit from receiving health education intervention with the opportunity to engage in lifestyle modifications that prevent or delay the onset of DCAN. Summarily, according to simple variables -- age, BMI, diabetic duration and hypertension, physicians can make appropriate clinical decisions for diabetic patients to treat their DCAN complications.

However, several potential limitations of this study should be mentioned. Because a cross-sectional study was used to create the screening model, we were unable to confirm a direct causal relationship among association factors and DCAN. Additionally, because all participants were aged between 30 years and 80 years, our model may be less practical for younger or older diabetic patients.

Conclusions
===========

This study offered evidence that our screening system has a high Sen and Spe for DCAN diagnosis in Chinese diabetic patients and can be applied as a self-assessment tool in primary medical care practice for identifying high-risk subjects with DCAN among Chinese diabetic patients.
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![Comparison of prevalence of diabetic cardiovascular autonomic neuropathy (DCAN) according to risk factors. (**A**) Comparison of DCAN prevalence according to age. DCAN prevalence was 20.83%, 24.71% and 36.36% in the 3 groups, respectively. Additionally, there were significant differences among the 3 groups (*P* for difference \<0.001 and *P* for a trend \<0.001). (**B**) Comparison of DCAN prevalence according to body mass index (BMI). DCAN prevalence was 27.79%, and 44.12% between BMI ≤30 kg/cm^2^ and BMI \>30 kg/cm^2^ group, respectively. There was a significant difference between the 2 groups (*P*=0.004). (**C**) Comparison of DCAN prevalence according to heart rate (HR). DCAN prevalence was 07.01%, 18.75%, 36.67% and 64.29% in the 4 groups, respectively. There were significant differences among the 4 groups (*P* for difference \<0.001 and *P* for a trend \<0.001). (**D**) Comparison of DCAN prevalence according to duration of diabetes (DM duration). DCAN prevalence was 18.18%, 26.35%, 36.25% and 51.72% in the 4 groups, respectively. There were significant differences among the 4 groups (*P* for difference \<0.001 and *P* for a trend \<0.001).](medscimonit-23-5354-g001){#f1-medscimonit-23-5354}

![Receiver operating characteristic curves showed the performance of each cardiovascular autonomic neuropathy risk score (CRS) in predicting prevalence of diabetic cardiovascular autonomic neuropathy (DCAN) in the exploratory set, total sample, validation set and external dataset. The 95% confidence interval (CI) is given in parentheses. AUC -- area under the curve. In exploratory set, AUC=0.779, 95%CI: 0.744--0.813, *P*\<0.001; in total sample, AUC=0.798, 95%CI: 0.752--0.844, *P*\<0.001; in validation set, AUC=0.756, 95%CI: 0.705--0.808, *P*\<0.001; and in external dataset, AUC=0.729, 95%CI: 0.601--0.857, *P*=0.002.](medscimonit-23-5354-g002){#f2-medscimonit-23-5354}

![Distribution of diabetic cardiovascular autonomic dysfunction (CAN) risk score (bottom bars) and DCAN prevalence (upper bars) against DCAN risk score in the modeling dataset.](medscimonit-23-5354-g003){#f3-medscimonit-23-5354}

###### 

The clinical baseline characteristics of individuals.

  Variable                  Modeling dataset   External dataset                           
  ------------------------- ------------------ ------------------ --------------- ------- ---------------
  Demographic information                                                                 
   N                        455                237                218             --      115
   Age years                62.8±8.61          62.94±8.98         62.64±8.19      0.606   58.34±9.9
   Gender male, %           208 (45.71%)       105 (43.88%)       103 (47.71%)    0.247   62 (53.91%)
   Height cm                162.12±8.15        161.93±8.06        162.32±8.26     0.471   163.31±8.84
   Weight kg                66.63±11.65        66.19±10.95        67.16±12.3      0.081   65.35±12.59
   SBP mmHg                 134.3±20.3         134.57±20.4        134.01±20.2     0.678   131.88±20.1
   DBP mmHg                 81.08±10.12        81.18±10.44        80.97±9.78      0.764   76.72±11.08
  Laboratory assays                                                                       
   FPG mmol/L               7.34±2.69          7.41±2.62          7.26±2.77       0.420   9.23±5.08
  6PBG mmol/L               11.98±4.42         11.93±4.37         12.03±4.49      0.744   13.07±5.44
   FINS uml/L               10.45±24.39        11.77±28.02        9.02±19.62      0.091   22.57±56.21
   TC mmol/L                5.38±1.11          5.35±1.1           5.4±1.13        0.490   4.63±1.21
   TG mmol/L                1.99±1.18          1.94±1.14          2.06±1.22       0.078   1.99±1.43
   HDL mmol/L               1.3±0.31           1.25±0.32          1.22±0.29       0.095   1.23±0.53
   LDL mmol/L               3.28±0.85          3.26±0.84          3.3±0.86        0.394   3±1.14
   SCr μmolL                81.37±24.04        81.17±26.28        81.58±21.37     0.797   72.67±32
  HRV indices                                                                             
   HR bpm                   75.11±10.41        74.77±10           75.52±10.78     0.110   73.26±11.41
   TP ms^2^                 747.3±682.53       758.08±673.82      735.59±692.46   0.620   658.07±680.86
   LF ms^2^                 166.57±225.93      170.15±215.56      162.67±236.87   0.618   145.83±225.52
   HF ms^2^                 152.15±188.51      155.75±208.43      147.36±163.1    0.230   119.25±174.13
   LF/HF                    1.84±2.12          1.81±2.14          1.87±2.1        0.651   1.98±2.36
  Medical history                                                                         
   Smoking yes, %           89 (19.56%)        43 (17.82%)        46 (21.46%)     0.145   13 (22.81%)
   DM duration years        5.24±6.45          5.25±6.72          5.24±6.14       0.972   10.57±8.23
   HTN yes, %               291 (63.96%)       157 (66.24%)       134 (61.47%)    0.134   67 (58.77%)
   HTN duration years       6.42±9.99          6.67±10.17         6.15±9.79       0.449   6.12±8.72
   MetS yes, %              330 (72.53%)       170 (71.31%)       160 (73.88%)    0.410   87 (75.65%)
   DCAN yes, %              132 (29.01%)       68 (28.69%)        64 (30.05%)     0.192   47 (40.87%)

Present the difference between exploratory set and validation set.

SBP -- systolic blood pressure; DBP -- diastolic blood pressure; FPG -- fasting plasma glucose; PBG -- plasma blood glucose; FINS -- fasting blood insulin; TC -- serum total cholesterol; TG -- triglyceride; HDL -- high-density lipoprotein cholesterol; LDL -- low density lipoprotein cholesterol; SCr -- serum creatinine; HR -- heart rate; TP -- total power of variance; LF -- low frequency; HF -- high frequency; MetS -- metabolic syndrome; HTN -- hypertension; DCAN -- diabetic cardiovascular autonomic neuropathy.

###### 

Simple risk score system for diabetic cardiovascular autonomic neuropathy in the exploratory set.

  Variable                 β       *P* value   OR (95%CI)             Risk score[\*](#tfn3-medscimonit-23-5354){ref-type="table-fn"}
  ------------------------ ------- ----------- ---------------------- ----------------------------------------------------------------
  Age (year)                                                          
   ≤50 years               0.000   --          1.00                   0
   50--65 years            0.452   0.006       1.57 (1.14--2.17)      2
   ≥66 years               0.912   \<0.001     2.48 (1.80--3.43)      4
  BMI (kg/m^2^)                                                       
   ≤30.0 kg/m^2^           0.000   --          1.00                   0
   \>30.0 kg/m^2^          0.750   0.018       2.12 (1.14--3.95)      3
  Diabetes duration                                                   
   \<1 year                0.000   --          1.00                   0
   1--9 years              0.492   0.001       1.78 (1.26--2.51)      2
   10--19 years            0.971   \<0.001     2.64 (2.16--3.22)      4
   ≥20 years               1.525   \<0.001     4.60 (3.76--5.16)      6
  Heart Rate (beats/min)                                              
   ≤63 bpm                 0.000   --          1.00                   0
   64--76 bpm              1.039   \<0.001     2.83 (2.82--3.50)      4
   77--84 bpm              1.891   \<0.001     6.23 (5.35--8.20)      8
   ≥85 bpm                 2.836   \<0.001     17.06 (13.77--21.12)   12

For each significant variable in the multiple logistic regression analysis, a risk score was calculated from the regression coefficients (β) dividing by a common factor (0.226) and rounding to the nearest integer.

###### 

Performance of the risk score at cutoff point of 12 in the four datasets.

  Variable                                                               Exploratory Set        Validation Set         Total sample           External dataset
  ---------------------------------------------------------------------- ---------------------- ---------------------- ---------------------- ----------------------
  Sensitivity (%)                                                        80.77 (74.05--87.49)   80.36 (73.42--87.29)   80.56 (74.07--87.05)   61.54 (54.67--68.41)
  Specificity (%)                                                        68.21 (57.85--78.57)   58.27 (47.72--68.81)   63.67 (52.94--74.4)    85.02 (74.64--95.4)
  Youden index (%)                                                       48.98 (40.47--57.5)    38.62 (30.08--47.17)   44.23 (35.96--52.5)    46.56 (37.85--55.27)
  PPV (%)                                                                50.55 (43.62--57.48)   45.27 (39.27--51.27)   47.54 (41.54--53.54)   72.75 (66.72--78.78)
  NPV (%)                                                                89.81 (86.07--93.55)   87.35 (83.71--90.99)   88.91 (85.63--92.19)   77.28 (73.52--81.04)
  Need testing (%)[\*](#tfn5-medscimonit-23-5354){ref-type="table-fn"}   34.33 (30.29--38.38)   43.55 (39.04--48.07)   38.7 (34.44--42.96)    33.38 (28.67--38.09)

PPV -- positive predictive value; NPV -- negative predictive value;

Proportion of the study sample with risk score above the cutoff value; The confidence intervals (CIs) for sensitivity, specificity, and predictive values were calculated using bootstrapping (1000).

###### 

Risk and predictive performance analysis of simple risk system for diabetic cardiovascular autonomic neuropathy in total sample an external dataset.

  Cutoff point       Total sample            External dataset                               
  ------------------ ----------------------- ----------------------- ---------------------- ----------------------
  Risk value         Low risk                High risk               Low risk               High risk
  Sensitivity (%)    97.22 (91.12--103.33)   25.22 (24.99--25.45)    96.15 (95.18--97.13)   23.08 (22.97--23.18)
  Specificity (%)    24.82 (14.41--35.23)    98.88 (88.21--109.55)   31.4 (20.43--42.37)    97.5 (87.23--107.77)
  Youden Index (%)   22.04 (13.48--30.6)     24.1 (15.9--32.3)       27.55 (18.83--36.28)   20.58 (11.74--29.42)
  PPV (%)            34.22 (27.3--41.15)     90.05 (83.47--96.63)    47.67 (41.38--53.95)   85.71 (79.34--92.09)
  NPV (%)            95.69 (92.19--99.19)    76.67 (73.53--79.82)    92.63 (89.07--96.19)   66.11 (63.07--69.14)
  \% Total sample    18.65 (13.72--23.59)    8.81 (4.53--13.09)      24.24 (19.68--28.8)    10.61 (6.6--14.62)

PPV -- positive predictive value; NPV -- negative predictive value; The confidence intervals (CIs) for sensitivity, specificity, and predictive values were calculated using bootstrapping (1000).

###### 

Comparison of individuals with diabetic cardiovascular autonomic neuropathy in high- and low- score groups.

  Variable             High-score group (12--26)   Low-score group (0--11)   *P* value
  -------------------- --------------------------- ------------------------- -----------
  N                    111                         21                        --
  Age years            64.71±8.91                  63.9±9.15                 0.592
  Gender male,%        57 (51.35%)                 8 (38.1%)                 0.115
  BMI kg/cm^2^         25.73±3.98                  25.02±4.96                0.306
  SBP mmHg             135.47±20.13                135.95±22.93              0.889
  DBP mmHg             81.3±9.79                   80.71±8.44                0.716
  FPG mmol/L           7.88±2.91                   7.87±4.38                 0.994
  PBG mmol/L           13±4.3                      13.69±4.74                0.350
  FINS uml/L           12±29.67                    21.32±60.67               0.129
  TC mmol/L            5.44±1.11                   5.43±1.24                 0.989
  TG mmol/L            2.3±1.39                    2.04±1.31                 0.263
  HDL mmol/L           1.26±0.27                   1.41±0.32                 0.001
  LDL mmol/L           3.29±0.9                    3.11±0.86                 0.227
  HR bpm               83.1±10.52                  71.74±6.27                \<0.001
  HTN duration years   7.88±10.88                  5.25±8.63                 0.150
  DM duration years    9.11±8.62                   3.62±3.98                 \<0.001
  Smoking yes, %       25 (22.52%)                 4 (19.05%)                0.618
  HTN yes, %           73 (65.77%)                 14 (66.67%)               0.910
  MetS yes, %          90 (81.08%)                 15 (71.43%)               0.155

BMI -- body mass index; SBP -- systolic blood pressure; DBP -- diastolic blood pressure; FPG -- fasting plasma glucose; PBG -- plasma blood glucose; TC -- serum total cholesterol; TG -- triglyceride; HDL -- high-density lipoprotein cholesterol; LDL -- low density lipoprotein cholesterol; HR -- heart rate; MetS -- metabolic syndrome; HTN -- hypertension.
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